KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Progyny (PGNY) Asset Writedowns and Impairment (2018 - 2025)

Historic Asset Writedowns and Impairment for Progyny (PGNY) over the last 8 years, with Q3 2025 value amounting to $4.3 million.

  • Progyny's Asset Writedowns and Impairment rose 3687.54% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 795.75%. This contributed to the annual value of $16.4 million for FY2024, which is 1774.86% down from last year.
  • According to the latest figures from Q3 2025, Progyny's Asset Writedowns and Impairment is $4.3 million, which was up 3687.54% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Progyny's Asset Writedowns and Impairment registered a high of $5.7 million during Q1 2025, and its lowest value of $2.3 million during Q1 2022.
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $4.1 million (2022), whereas its average is $4.0 million.
  • As far as peak fluctuations go, Progyny's Asset Writedowns and Impairment surged by 39288.79% in 2021, and later crashed by 3997.72% in 2024.
  • Quarter analysis of 5 years shows Progyny's Asset Writedowns and Impairment stood at $2.6 million in 2021, then skyrocketed by 60.38% to $4.1 million in 2022, then grew by 18.57% to $4.9 million in 2023, then fell by 24.84% to $3.7 million in 2024, then increased by 18.19% to $4.3 million in 2025.
  • Its Asset Writedowns and Impairment stands at $4.3 million for Q3 2025, versus $5.4 million for Q2 2025 and $5.7 million for Q1 2025.